

ARID1A Regulates E-Cadherin Expression in Colorectal Cancer Cells: A Promising Candidate Therapeutic Target

Mehran Erfani

Shiraz University of Medical Sciences

Mozhdeh Zamani

Shiraz University of Medical Sciences

Seyed Younes Hosseini

Shiraz University of Medical Sciences

Zohreh Mostafavi-Pour

Shiraz University of Medical Sciences

Sayed Mohammad Shafiee

Shiraz University of Medical Sciences

Mohammadreza Saeidnia

Shiraz University of Medical Sciences

Pooneh Mokarram (✉ mokaram2@gmail.com)

Shiraz University of Medical Sciences <https://orcid.org/0000-0002-9717-0473>

Research Article

Keywords: Colorectal cancer, ARID1A, E-cadherin, β -catenin

Posted Date: June 4th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-553289/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background Metastasis is a major cause of death in colorectal cancer (CRC) patients, and the epithelial–mesenchymal transition (EMT) has been known to be a crucial event in cancer metastasis.

Downregulated expression of AT-rich interaction domain-containing protein 1A (*ARID1A*), a bona fide tumor suppressor gene, plays an important role in promoting EMT and CRC metastasis, but the underlying molecular mechanisms remain poorly understood. Here, we evaluated the impact of *ARID1A* knockdown and overexpression on the expression of EMT-related genes, *E-cadherin* and *β-catenin*, in human CRC cells.

Methods and Results The expression levels of *ARID1A*, *E-cadherin* and *β-catenin* in CRC cell lines were detected via real-time quantitative PCR (qPCR) and western blot. *ARID1A* overexpression and shRNA-mediated knockdown were performed to indicate the effect of *ARID1A* expression on *E-cadherin* and *β-catenin* expression in CRC cell lines. The effect of *ARID1A* knockdown on the migration ability of HCT116 cells was assessed using wound-healing assay. We found that the mRNA and protein expression of adhesive protein E-cadherin was remarkably downregulated in response to shRNA-mediated *ARID1A* knockdown in HCT116 and HT29 cells. Conversely, overexpression of *ARID1A* in SW48 cells significantly increased E-cadherin expression. In addition, *ARID1A* silencing promoted the migration of HCT116 cells. *ARID1A* knockdown and overexpression did not alter the level of *β-catenin* expression.

Conclusion Our study demonstrates that E-cadherin levels were closely correlated with *ARID1A* expression. Thus, *ARID1A* downregulation may promote CRC metastasis through decreasing EMT-related protein E-cadherin and promoting epithelial cell movement. *ARID1A* could represent a promising candidate therapeutic target for CRC.

Introduction

Colorectal cancer (CRC) is the third most common cancer worldwide, and is a major cause of cancer mortality, accounting for approximately one-tenth of all tumor-related deaths in the world annually [1]. Metastasis is the primary cause of treatment failure and death in CRC [2, 3]. Thus, a better understanding of the molecular mechanism underlying colorectal cancer metastasis may lead to new therapeutic strategies.

AT-rich interactive domain-containing protein 1A (*ARID1A*), a bona fide tumor suppressor gene, encodes a key subunit of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin-remodeling complex. The SWI/SNF complex modulates the DNA accessibility to co-regulatory and transcriptional machinery and acts as a transcriptional regulator of genes involved in many important cellular processes, including proliferation, development, differentiation and DNA damage repair [4, 5]. As a subunit of SWI/SNF complex, *ARID1A* is assumed to play a crucial role in SWI/SNF complex targeting to enhancers and in maintaining their chromatin accessibility as it has DNA binding activity. Upon *ARID1A* inactivation, defects in targeting SWI/SNF and control of enhancer activity impair development and differentiation

programs and cause extensive dysregulation of gene expression, thus driving tumor formation [6]. For instance, in ARID1A-deficient colon cancer, SWI/SNF is lost from thousands of enhancers with corresponding effects on gene expression [7].

ARID1A is one of the most frequently mutated tumor suppressors in various human cancers [8]. As data have emerged from the Cancer Genome Atlas project (TCGA), mutations in *ARID1A* have been found at high frequencies in CRC. With an estimated mutation rate of 10–40%, *ARID1A* is the third most significantly mutated gene in human CRC, following APC and P53 [7, 9, 10]. Furthermore, mutations in *ARID1A* are generally inactivating (insertion/deletion) and leading to *ARID1A* expression loss [8, 10]. Apart from inactivating mutations, aberrant DNA methylation, has also been reported as an important mechanism for suppressing ARID1A expression in CRC [11]. Available data support an important role of ARID1A inactivation in promoting formation and metastasis of CRC. *ARID1A* knockout in mice per se, drives the formation of invasive colon tumors [7]. In addition, in a clinical study of CRC, Kishida et al. revealed that negative *ARID1A* expression was correlated with early onset and lymphatic invasion [12]. It has been found that *ARID1A* knockout can enhance the migratory activity of cancer cells by promoting epithelial mesenchymal transition (EMT) [13-16]. EMT has been known to be a crucial event in cancer invasion and metastasis [17, 18]. During EMT, cancer cells lose their cell–cell adhesions and polarity and thereby acquire enhanced invasive and migratory properties [17]. However, the role of ARID1A in expression of genes associated with EMT and cell-cell adhesion in CRC remains poorly understood. Therefore, in this study, we aimed to investigate the impact of *ARID1A* knockdown and overexpression on the expression of EMT-related genes, *E-cadherin* and *β-catenin*, in human CRC cells.

Materials And Methods

Cell culture

HEK293T cell line and six CRC cell lines (HCT116, HT 29, SW48, SW742, SW480 and LS180) were purchased from the National Cell Bank of Iran (Pasteur Institute, Tehran, Iran). HCT116, HT 29, SW48, SW742 and SW480 cells were cultured in RPMI 1640 medium (#11875093, Thermo Fisher Scientific, Inc., Bartlesville, OK, USA) and HEK293T and LS180 cells were cultured in DMEM medium (#12430062, Thermo Fisher Scientific, Inc., Bartlesville, OK, USA) containing 10% fetal bovine serum (Gibco-BRL), 1% penicillin(#16000044, Thermo Fisher Scientific, Inc., Bartlesville, OK, USA) and 1% streptomycin (HyClone; GE Healthcare Life Sciences, Logan, UT, USA), in a humidified CO₂ (5%) incubator at 37°C, and regularly checked and confirmed to be mycoplasma-free.

Plasmids and lentivirus production

Overexpression plasmid of pcDNA 6- ARID1A was obtained from addgene (#39311, Addgene plasmid) for the overexpression assay. Empty vector was used as a negative control. The short hairpin RNA (shRNA) lentiviral plasmid (pLKO.1) which contains a puromycin resistance gene was obtained from Addgene (#10878, pLKO.1 - TRC Cloning Vector, Addgene). The shRNA oligonucleotide against *ARID1A* gene (oligo ID: TRCN0000059090) with the sequence of 5'- CCTCTCTTATACACAGCAGAT -3' was cloned into the

pLKO.1 vector. A pLKO.1-puro Empty Vector (#RHS4080, Open Biosystems) was also used to produce empty lentivirus as a control. The empty lentivirus and lentivirus encoding *ARID1A* shRNA were produced using HEK293T cells transfected with pLKO.1 plasmids and the second generation packaging system, pMD2.G (#12259, Addgene plasmid) and pSPAX2 (#12260, Addgene plasmid). Briefly, about 80% confluent HEK293T cells were co-transfected with 0.5 µg of the envelope protein-coding plasmid (pMD2.G), and 1.5 µg of the packaging construct (pSPAX2) together with 2 µg of pLKO.1 vector encoding *ARID1A* shRNA or negative control pLKO.1 Empty Vector using a standard polyethylenimine (PEI) mediated method [19]. After 48 hours, the virus-containing media was collected, centrifuged (1,250 rpm for 5 minutes), and stored in small aliquots at -80°C.

Generation of the HCT116 and HT29 cells stably expressing shRNA against *ARID1A*

HCT116 and HT29 cells were seeded in 6-well plates. After 24 hours, the lentiviral supernatant containing either a lentivirus expressing *ARID1A* shRNA or an empty lentivirus as a control was added at MOI (multiplicity of infection) of 5-50 together with 8 µg/ml polybrene (#sc-134220, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). 24 hours later, the transduction medium was replaced with fresh complete medium and puromycin (#sc-108071, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) selection (1 µg/ml) was started 72 hours post transfection. Approximately, in every 2-3 days, the culture media was aspirated and replaced with freshly prepared selective media. After 3 weeks under puromycin selection the remaining resistant clones were assessed for knock down efficacy. *ARID1A* Knockdown efficacy was assessed by immunoblotting and qPCR

***ARID1A* gene transfection into SW48 cells**

SW48 cells were transfected with 2 µg pcDNA6- *ARID1A* or 2 µg pcDNA6 (as a negative control). Cell transfection was performed using Lipofectamine 2000 (#11668030, Invitrogen; Thermo Fisher Scientific, Inc. USA) according to the manufacturer's instructions. The efficiency of the transfection was examined 48 hours post-transfection using real-time quantitative PCR and Western blotting.

RNA extraction and Real-time PCR assay

RNA of cultured cells was extracted using the Tripure RNA isolation kit (#11667165001, Roche Applied Science, Germany) based on the manufacturer's guidelines. cDNA synthesis was conducted by RevertAid First Strand cDNA Synthesis Kit (#K1622, Thermo Fisher Scientific, USA). mRNA analysis of *ARID1A* was determined by real-time quantitative PCR (qPCR) using SYBR Green master mix (#4309155, Thermo Fisher Scientific, USA) on an ABI 7500 Sequence Detection System (Applied Biosystems, USA). *GAPDH* was used as an internal housekeeping gene. Relative gene expression levels were calculated using the $2^{-\Delta\Delta C_t}$ method. The primers used in this study are listed in Table 1.

Western blot analysis

Cultured cells were lysed using ice-cold lysis buffer in the presence of a protease inhibitor cocktail (Roche Applied Science) and the protein concentration was quantified using a Pierce BCA protein assay kit (#23225, Thermo Fisher Scientific, USA). Proteins with an equal amount were separated by 12% SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were then blocked using 5% skim milk/PBS for 1 h. After blocking, membranes were incubated with the following primary antibodies overnight at 4°C: ARID1A (#sc-373784; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), β -catenin (#sc-7963; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), E-cadherin (#sc-71009; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and GAPDH (#ab181602; Abcam, UK) as an internal control. Each membrane was subsequently washed with TBST three times and incubated with a corresponding HRP-conjugated secondary antibody at room temperature for 1 hr. Protein detection was performed using a Pierce™ enhanced chemiluminescence (ECL) western blotting substrate (#32209, Thermo Fisher Scientific, Inc., Bartlesville, OK, USA). Band intensity data was obtained using Image lab software (version 5.2, Bio-Rad).

Wound healing (Scratch) migration assay

In order to determine the cell migration, the HCT116 cells were cultured in 6-well plates to confluence. Subsequently, the monolayer cells were scratched using 200 μ l pipette tip from the top to the bottom of the culture plates. After the debris was removed with PBS, the cells were further maintained at 37°C in a humidified incubator with 5% CO₂. Wounded area was visualized after 0, 24 and 48 h using an Olympus CX31 light microscope (Olympus Corporation, Tokyo, Japan) and calculated by NIH ImageJ software (<https://imagej.nih.gov/ij/>). Cell motility was estimated through the quantification of the % of recovery using the equation: $R (\%) = [1 - (\text{wound area at } T_t / \text{wound area at } T_0)] \times 100$, where T_0 is the wounded area at 0 h and T_t is the wounded area after t.

Statistical analysis

All the experiments were repeated at in triplicate and all data were expressed as mean \pm SD. The statistical package IBM SPSS Statistics (IBM Corp. Released 2017. The IBM SPSS Statistics for Windows was used for all analyses (Version 25.0. Armonk, NY: IBM Corp.). Graphs were performed using Prism version 6.00 (GraphPad Software, Inc., San Diego, CA, USA). The one-way ANOVA, accompanied by Tukey's multiple comparison tests were performed to analyze data. Differences with a P value ≤ 0.05 were statistically significant.

Results

The efficiency of overexpression and shRNA-mediated knockdown of *ARID1A* in CRC cell lines

We examined the expression of *ARID1A* in a panel of CRC cell lines using qPCR (Fig. 1a). Among the 6 CRC cell lines, the highest expression level of *ARID1A* was in the HCT116 and HT29 cells, whereas SW48 cells lacked *ARID1A* expression (Fig. 1a). Thus, these cells were selected for subsequent knockdown and overexpression analyses, respectively. We stably silenced *ARID1A* in HCT116 and HT29 cells using

ARID1A shRNA lentivirus and overexpressed *ARID1A* in SW48 cells by plasmid transfection. Successful knockdown and overexpression of *ARID1A* in these cells were confirmed using Western blot and qPCR analysis (Fig. 1b and c).

***ARID1A* silencing suppresses the expression of E-cadherin protein and mRNA, whereas the *ARID1A* overexpression exerts an opposite effect**

Western blot analysis and RT-qPCR indicated that the HCT116 and HT29 cells with stable knockdown of *ARID1A* by *ARID1A* shRNA virus exhibited a lower expression of E-cadherin protein and mRNA as compared to cells transduced with control virus carrying pLKO.1. On the other hand, the SW48 cells transfected with pCDNA6-*ARID1A* exhibited a higher expression of E-cadherin protein and mRNA as compared to the control group of cells lacking *ARID1A* expression (Fig. 2). The above results suggest that *ARID1A* may modulate E-cadherin expression.

β -catenin remains stable regardless of *ARID1A* silencing or overexpression

To identify the role of *ARID1A* in the expression of β -catenin in CRC cells, protein and mRNA levels of β -catenin in CRC cells were analyzed after overexpression or stable knockdown of *ARID1A*. As shown in Fig. 2, the expression of β -catenin remained largely stable regardless of *ARID1A* silencing or overexpression in CRC cells.

Knockdown of *ARID1A* promotes HCT116 cells migration

The migration ability of HCT116 cells was examined by wound healing assay. Microscopic examination after wounding revealed that HCT116 cells transduced with *ARID1A* shRNA lentivirus have obviously increased ability of wound closure at all time points (up to 48 h post-scratch) compared to HCT116 cells transduced with control lentivirus (Fig. 3).

Discussion

EMT, an absolute requirement for tumor metastasis and invasion, plays a key role in cancer progression, including CRC [17, 18, 20]. Due to its emerging role as a pivotal driver of tumorigenesis, inhibiting EMT is an attractive therapeutic strategy in combating metastasis in cancer patients [21]. The hallmark of EMT is the decreased expression of the E-cadherin protein [17, 22, 23]. When E-cadherin is downregulated, epithelial cells lose their polarity and cell–cell adhesion, and EMT then occurs. Therefore, the downregulation mechanism of E-cadherin is a key topic of EMT research [17, 22]. In recent years, an increasing number of studies have found that *ARID1A* downregulation is associated with EMT and tumor invasion via the repression of E-cadherin in several different types of cancer including some types of gastrointestinal cancers [13-15, 24]. Although, decreased expression of *ARID1A* protein has been associated with enhanced invasion and metastasis of colorectal carcinoma in mice and humans [7, 12]; however, there is limited evidence for the *ARID1A* role in regulating E-cadherin expression in CRC. To address this issue, we sought to delineate the impact of *ARID1A* knockdown and overexpression on the

expression of E-cadherin protein and mRNAs in CRC cells. Here, we demonstrated that the expression of E-cadherin was strongly correlated with that of ARID1A. ShRNA-mediated knockdown of *ARID1A* significantly downregulated E-cadherin expression in HCT116 and HT29/219 cells. Conversely, in the SW48 cells transfected with *ARID1A* overexpression vector, *E-cadherin* expression was significantly upregulated. These results are in good agreement with the findings from the only available experimental study in CRC, in which Mathur et al. indicated the *E-cadherin* downregulation in HCT116 isogenic lines with monoallelic (*ARID1A*^{+/-}) or biallelic (*ARID1A*^{-/-}) deletion of *ARID1A* [7]. Importantly, our results were also consistent with data from the previous studies, which suggest that *ARID1A* knockdown decreased the expression of E-cadherin, whereas *ARID1A* overexpression increased the expression of E-cadherin in human gastric, breast and hepatocellular cancer cells [14, 15, 25]. Moreover, *ARID1A* knockdown strongly downregulated *E-cadherin* expression in cells derived from nasopharyngeal and neuroblastoma carcinomas [24, 26]. Notably, controversial report also exists. In a clinical study of esophageal squamous cell carcinoma, Ozawa et al. found that *ARID1A* expression status did not significantly correlate with *E-cadherin* expression levels of the patients [27]. Additional studies would be helpful to explore the exact mechanism by which ARID1A regulates E-cadherin, such as ChIP-sequencing of histone markers of repression and activation coupled with ATAC-seq [28] will be useful to examine the interplay of ARID1A and chromatin accessibility of E-cadherin in CRC cells or detecting of ARID1A effects on transcriptional repressors of E-cadherin such as Slug, Zeb, Twist, Snail and some microRNAs especially the miR-200 family [17].

Considering that E-cadherin downregulation marks the initiation of EMT and cancer cells invasion and metastasis, we postulated that *E-cadherin* downregulation by *ARID1A* silencing may partly account for enhanced migration activity of CRC cells. Therefore, using wound healing, we also noted that knockdown of *ARID1A* significantly enhanced the migration activity of the HCT116 cells, consistent with the data reported in pancreas, kidney, neuroblastoma, gastric, breast, and liver cancers, in which loss of ARID1A promoted cell migration and invasion [13, 15, 16, 25, 29, 30].

β -catenin, a major component of the canonical Wnt signaling pathway, has a crucial role in the negative regulation of E-cadherin expression and the EMT induction [20, 31]. Upon Wnt stimulation, β -catenin is stabilized, translocate to the nucleus where it triggers constitutive activation of Wnt target genes. Aberrant activation of the Wnt pathway underlies many cancers including CRC [20, 32-34]. In this study, *ARID1A* knockdown or overexpression did not alter the expression level of β -catenin. This finding is in agreement with a previous study in human gastric cells, in which the expression of β -catenin remained largely stable regardless of *ARID1A* silencing [15]. With respect to the ARID1A role in the regulation of β -catenin, the documented results to date are controversial. For instance, in the only available experimental study in CRC, Mathur et al. found that *Arid1a*^{fl/fl} mice drive colorectal tumorigenesis by a mechanism that is independent of Wnt signaling and distinct from established genetic models of colon cancer [7]. In the mentioned research, β -catenin localized exclusively outside of the nucleus in mice colon tumors, indicating that *ARID1A* inactivation does not cooperate with aberrant Wnt signaling in driving tumorigenesis [7]. In contrast, *ARID1A* silencing in human gastric and neuroblastoma cells induced

disassociation of the E-cadherin/ β -catenin adhesion complex at the membrane and a redistribution of β -catenin from the plasma membrane to the nucleus, where β -catenin triggers the EMT process [15, 26]. Additional studies are needed to elucidate the effect of the manipulation of *ARID1A* expression on nuclear translocation of β -catenin and the activation of Wnt signaling in CRC cells.

Conclusions

Our findings, together with those of previous studies, further demonstrate that *ARID1A* regulates E-cadherin expression in cancer cells. Considering that downregulation or loss of E-cadherin expression can activate EMT, therefore, our data suggest that *ARID1A* downregulation may contribute to enhancing the migratory and invasive abilities of CRC cells. In addition, we present evidence for the role of E-cadherin as one potential therapeutic target for *ARID1A*-deficient tumors as it was affected by *ARID1A* re-expression.

Declarations

Funding This work was supported by the Shiraz University of Medical Sciences [Grant number: 17288]

Conflicts of interest The authors declared that they have no conflicts of interest.

Availability of data and materials All data are included in this article and datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Code Availability Not applicable

Authors Contributions

Pooneh Mokarram and Mehran Erfani contributed to the study conception and design. Material preparation, data collection and analysis were performed by Mehran Erfani, Mozhdeh Zamani, Seyed Younes Hosseini, Zohreh Mostafavipour and Sayed Mohammad Shafiee. The first draft of the manuscript was written by Mehran Erfani and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Ethical Approval Ethics approval was obtained from the Ethics Committee of Shiraz University of Medical Sciences prior to this study (IR.SUMS.REC.1398.1390).

Consent for participate Not applicable

Consent for publication All authors have agreed to publish this manuscript.

Acknowledgment The authors would like to express their sincere gratitude to Shiraz University of Medical Sciences for financially supporting the study (No.17288).

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 68(6):394-424. <https://doi.org/10.3322/caac.21492>
2. Brenner H, Kloor M, Peter Pox CH (2014) colorectal cancer. *Lancet* 383(9927):1490-1502. [https://doi.org/10.1016/S0140-6736\(13\)61649-9](https://doi.org/10.1016/S0140-6736(13)61649-9)
3. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S (2011) KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. *Lancet Oncol* 12(6):594-603. [https://doi.org/10.1016/S1470-2045\(10\)70209-6](https://doi.org/10.1016/S1470-2045(10)70209-6)
4. Euskirchen G, Auerbach RK, Snyder M (2012) SWI/SNF chromatin-remodeling factors: multiscale analyses and diverse functions. *J Biol Chem* 287(37):30897-30905. <https://doi.org/10.1074/jbc.R111.309302>
5. Shen J, Peng Y, Wei L, Zhang W, Yang L, Lan L, Kapoor P, Ju Z, Mo Q, Shih IM (2015) ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. *Cancer Discov* 5(7):752-767. <https://doi.org/10.1158/2159-8290.CD-14-0849>
6. Mathur R (2018) ARID1A loss in cancer: towards a mechanistic understanding. *Pharmacol Ther* 190:15-23. <https://doi.org/10.1016/j.pharmthera.2018.05.001>
7. Mathur R, Alver BH, San Roman AK, Wilson BG, Wang X, Agoston AT, Park PJ, Shivdasani RA, Roberts CW (2017) ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. *Nat Genet* 49(2): 296. <https://doi.org/10.1038/ng.3744>
8. Jones S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, Schmidt MK, Markowitz S, Yan H, Bigner D (2012) Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. *Hum Mutat* 33(1):100-103. <https://doi.org/10.1002/humu.21633>
9. Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, Fowler G, Kovar CHL, Lewis LR, Morgan MB, Newsham IF, Reid JG, Santibanez J, Shinbrot E, Trevino LR, Wu YQ, Wang M, Gunaratne P, Donehower LA, Creighton CHJ, Wheeler DA, Gibbs RA (2012) Comprehensive molecular characterization of human colon and rectal cancer. *Nature* 487(7407):330-337. <https://doi.org/10.1038/nature11252>
10. Cajuso T, Hänninen UA, Kondelin J, Gylfe AE, Tanskanen T, Katainen R, Pitkänen E, Ristolainen H, Kaasinen E, Taipale M (2014) Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer. *Int J Cancer* 135(3):611-623. <https://doi.org/10.1002/ijc.28705>
11. Erfani M, Hosseini SV, Mokhtari M, Zamani M, Tahmasebi K, Alizadeh Naini M, Taghavi A, Carethers JM, Koi M, Brim H, (2020) Altered ARID1A expression in colorectal cancer. *BMC cancer* 20:1-13. <https://doi.org/10.1186/s12885-020-6706-x>
12. Kishida Y, Oishi T, Sugino T, Shiomi A, Urakami K, Kusuvara M, Yamaguchi K, Kitagawa Y, Ono H (2019) Associations between loss of ARID1A expression and Clinicopathologic and genetic variables in T1 early colorectal Cancer. *Am J Clin Pathol* 152(4):463-470. <https://doi.org/10.1093/ajcp/aqz062>

13. Somsuan K, Peerapen P, Boonmark W, Plumworasawat I, Samol R, Sakulsak N, Thongboonkerd V (2019) ARID1A knockdown triggers epithelial-mesenchymal transition and carcinogenesis features of renal cells: role in renal cell carcinoma. *FASEB J* 33(11):12226-12239. <https://doi.org/10.1096/fj.201802720RR>
14. Wang T, Gao X, Zhou K, Jiang T, Gao S, Liu P, Zuo X, Shi X (2020) Role of ARID1A in epithelial-mesenchymal transition in breast cancer and its effect on cell sensitivity to 5-FU. *Int J Mol Med* 46(5):1683-1694. <https://doi.org/10.3892/ijmm.2020.4727>
15. Yan HB, Wang XF, Zhang Q, Tang ZQ, Jiang YH, Fan HZ, Sun YH, Yang PY, Liu F (2014) Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription. *Carcinogenesis* 35(4):867-876. <https://doi.org/10.1093/carcin/bgt398>
16. Wang W, Friedland SC, Guo B, O'Dell MR, Alexander WB, Whitney-Miller CL, Agostini-Vulaj D, Huber AR, Myers JR, Ashton JM (2019) ARID1A, a SWI/SNF subunit, is critical to acinar cell homeostasis and regeneration and is a barrier to transformation and epithelial-mesenchymal transition in the pancreas. *Gut* 68(7):1245-1258. <http://dx.doi.org/10.1136/gutjnl-2017-315541>
17. Bates RC, Mercurio (2005) A The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. *Cancer Biol Ther* 4(4):371-376. <https://doi.org/10.4161/cbt.4.4.1655>
18. Bronsert P, Enderle-Ammour K, Bader M, Timme S, Kuehs M, Csanadi A, Kayser G, Kohler I, Bausch D, Hoepfner J (2014) Cancer cell invasion and EMT marker expression: a three-dimensional study of the human cancer–host interface. *J Pathol* 234(3):410-422. <https://doi.org/10.1002/path.4416>
19. Kuroda H, Kutner RH, Bazan NG, Reiser J (2009) Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection. *J Virol Methods* 157(2) 113-121. <https://doi.org/10.1016/j.jviromet.2008.11.021>
20. Chen HN, Yuan K, Xie N, Wang K, Huang Z, Chen Y, Dou Q, Wu M, Nice EC, Zhou ZG (2016) Pdlim1 stabilizes the e-cadherin/β-catenin complex to prevent epithelial–mesenchymal transition and metastatic potential of colorectal cancer cells. *Cancer Res* 76(5):1122-1134. <https://doi.org/10.1158/0008-5472.CAN-15-1962>
21. Davis FM, Stewart TA, Thompson EW, Monteith GR (2014) Targeting EMT in cancer: opportunities for pharmacological intervention. *Trends Pharmacol Sci* 35(9):479-488. <https://doi.org/10.1016/j.tips.2014.06.006>
22. Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP, Looi CY (2019) The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. *Cells* 8(10):1118. <https://doi.org/10.3390/cells8101118>
23. Druzhkova I, Ignatova N, Prodanets N, Kiselev N, Zhukov I, Shirmanova M, Zagainov V, Zagaynova E (2019) E-cadherin in colorectal cancer: relation to chemosensitivity. *Clin Colorectal Cancer* 18(1):e74-e86. <https://doi.org/10.1016/j.clcc.2018.10.003>
24. Yang Y, Wang X, Yang J, Duan J, Wu Z, Yang F, Zhang X, Xiao S (2019) Loss of ARID1A promotes proliferation, migration and invasion via the Akt signaling pathway in NPC. *Cancer Manag Res*

11:4931. <https://doi.org/10.2147/CMAR.S207329>

25. He F, Li J, Xu J, Zhang S, Xu Y, Zhao W, Yin Z, Wang X (2015) Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma. *J Exp Clin Cancer Res* 34(1):47. <https://doi.org/10.1186/s13046-015-0164-3>
26. Li C, Xu Z, Zhao Z, An Q, Wang L, Yu Y, Piao D (2017) ARID1A gene knockdown promotes neuroblastoma migration and invasion. *Neoplasma* 64(3):367-376. https://doi.org/10.4149/neo_2017_307
27. Ozawa Y, Nakamura Y, Fujishima F, Felizola SJ, Takeda K, Okamoto H, Ito K, Ishida H, Konno T, Kamei T (2015) Decreased expression of ARID1A contributes to infiltrative growth of esophageal squamous cell carcinoma. *Tohoku J Exp Med* 235(3):185-191. <https://doi.org/10.1620/tjem.235.185>
28. Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ (2013) Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. *Nat Methods* 10(12):1213-1218. <https://doi.org/10.1038/nmeth.2688>
29. Sun X, Wang SC, Wei Y, Luo X, Jia Y, Li L, Gopal P, Zhu M, Nassour I, Chuang JC (2017) Arid1a has context-dependent oncogenic and tumor suppressor functions in liver cancer. *Cancer cell* 32(5):574-589. e576. <https://doi.org/10.1016/j.ccell.2017.10.007>
30. Takao C, Morikawa A, Ohkubo H, Kito Y, Saigo C, Sakuratani T, Futamura M, Takeuchi T, Yoshida K (2017) Downregulation of ARID1A, a component of the SWI/SNF chromatin remodeling complex, in breast cancer. *J Cancer* 8(1):1-8. <https://doi.org/10.7150/jca.16602>
31. Goetz JG, Minguet S, Navarro-Lérida I, Lazcano JJ, Samaniego R, Calvo E, Tello M, Osteso-Ibáñez T, Pellinen T, Echarri A (2011) Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. *Cell* 146(1):148-163. <https://doi.org/10.1016/j.cell.2011.05.040>
32. Fearon ER (2011) Molecular genetics of colorectal cancer. *Annu Rev Pathol* 6(1):479-507. <https://doi.org/10.1146/annurev-pathol-011110-130235>
33. Guinney J, Dienstmann R, Wang X, De Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P (2015) The consensus molecular subtypes of colorectal cancer. *Nat Med* 21(11):1350-1356. <https://doi.org/10.1038/nm.3967>
34. McCart AE, Vickaryous NK, Silver A (2008) Apc mice: models, modifiers and mutants. *Pathol Res Pract* 204(7):479-490. <https://doi.org/10.1016/j.prp.2008.03.004>

Tables

Table 1
Sequences of primers used for Real-Time RT-PCR.

Gene	Forward (5'-3')	Reverse (5'-3')
ARID1A	CAGTACCTGCCTCGCACATA	GCCAGGAGACCAGACTTGAG
E-cadherin	ATTTTTCCCTCGACACCCGAT	TCCCAGGCGTAGACCAAGA
β -catenin	AAAATGGCAGTGCGTTTAG	TTTGAAGGCAGTCTGTCGTA
GAPDH	CGACCACTTTGTCAAGCTCA	AGGGGTCTACATGGCAACTG

Figures




Figure 1

ARID1A relative mRNA expression in several colorectal carcinoma cell lines and efficiency of overexpression and shRNA-mediated knockdown of ARID1A. (a) Endogenous expression of ARID1A was examined in HCT116, HT29, LS180, SW742 by qPCR. SW48 cell line was utilized as a reference, with an expression level set to 1.0, and expressions in all other cell lines were presented as an n-fold difference, compared to the SW48. Analysis of western blot (b) and qPCR (c) showed reduction in ARID1A

expression in HCT116 and HT29 cells transduced with ARID1A shRNA virus, compared to control virus transduced cells, while pCDNA6-ARID1A plasmid transfection markedly enhanced ARID1A levels in SW48 cells. The ARID1A expression was normalized relative to GAPDH. For panel A and C, Mean \pm standard deviation (SD) of three experiments is reported. (**p < 0.01).




Figure 2

Effects of ARID1A on the protein and mRNA expression of E-cadherin and β -catenin in HCT116, HT29 and SW48 cells. Western blot (a) and qPCR (b) demonstrates that ARID1A stable knockdown results in reduced expression of E-cadherin in both HCT116 and HT29 cells, while induction of ARID1A expression leads to upregulation of E-cadherin in SW48 cells. The β -catenin expression is not significantly affected following ARID1A knockdown or overexpression. Values are expressed as mean \pm SD (n=3). (**P < 0.01)




Figure 3

Knockdown of ARID1A promotes HCT116 cells migration. (a) The Effects of ARID1A knockdown on migratory activity of HCT116 cells was examined by wound healing assay. Representative images of wound healing assay at indicated time points (0, 24 and 48 h after the scratch) are shown. Dashed line indicates boundary of the scratched wound. (b) Cell motility was estimated through the quantification of the % of recovery using the equation detailed in section of Materials and Methods. Data were presented as means \pm SD from three replicates. (* $p < 0.05$).